Gabapentin Enacarbil Extended‐Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial

BACKGROUND: We reanalyzed a multisite 26‐week randomized double‐blind placebo‐controlled clinical trial of 600 mg twice‐a‐day Gabapentin Enacarbil Extended‐Release (GE‐XR), a gabapentin prodrug, designed to evaluate safety and efficacy for treating alcohol use disorder. In the original analysis (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Laska, Eugene M., Siegel, Carole E., Lin, Ziqiang, Bogenschutz, Michael, Marmar, Charles R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Behavior, Treatment and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540534/
https://www.ncbi.nlm.nih.gov/pubmed/33460198
http://dx.doi.org/10.1111/acer.14414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540534/
https://www.ncbi.nlm.nih.gov/pubmed/33460198
http://dx.doi.org/10.1111/acer.14414

Ejemplares similares